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Introduction 
Nuclear Medicine has been a well-established component of the diagnostic work up of 
several paediatric nephro-urological clinical conditions for at least 40 years. Despite vast 
technological advances in radiology over the last half century, the functional information 
provided by radionuclide studies remains a cornerstone for the management of many 
paediatric diseases.  
Nephro-urology constitutes the bulk of the workload of a paediatric nuclear medicine unit. 
This is due to the relative frequency of urinary tract infections and the variety of congenital 
renal anomalies, such as hydro-ureteronephrosis, nowadays detectable with antenatal 
ultrasound, and the increasing incidence of acquired conditions, such as renal calculi, which 
sometimes may require further evaluation with a functional study. 
A major advantage for the use of Nuclear Medicine in paediatric nephro-urology is that these 
techniques do not require sophisticated pieces of equipment, a single head gamma camera 
being sufficient for almost the entirety of paediatric examinations. Sedation or general 
anaesthesia is almost unnecessary and, in the case of dynamic renography, it can actually 
be detrimental due to its effect on diuresis. Central to successful paediatric radionuclide 
studies are human and environmental factors, in particular a team of child friendly 
radiographers / technicians (specially trained in paediatric nuclear medicine practice), who 
know how to interact with the child and family, winning their trust and confidence and 
ensuring that the child is relaxed and co-operative on the gamma camera couch during the 
test. Special skills in venepuncture are also essential, as is an appropriately decorated 
nuclear medicine unit that helps relieve fear and anxiety in the child, often associated with 
hospital visits.  
 
Radionuclide renal scintigraphy encompasses several nuclear medicine investigations: 
dimercaptosuccinic acid (Tc-99m-DMSA) renal scintigraphy, mercaptoacetyltriglycine (Tc-
99m-MAG3) or diethylenetriaminepentaacetic acid (Tc-99m-DTPA) dynamic renal 
scintigraphy and radionuclide micturating cystography (direct and indirect radionuclide 
cystography). These techniques, together with ultrasonography (US), fluoroscopic 
micturating cystogram (MCUG) or magnetic resonance imaging (MRI), and occasionally 
computerised tomography (CT), of the renal tract, provide functional data for the diagnosis 
and management of children with suspected genito-urinary tract problems, contributing to a 
holistic morpho-functional assessment of the paediatric urinary tract. 
The framework for each of the renal scintigraphy procedures has been published and 
revised by both the European and North American (NA) societies (EANM and SNMMI, 
respectively) in their corresponding guidelines (1-7). Comprehensive highly informative 
reviews on different aspects of paediatric nuclear medicine have also been published in the 
last 10 years (8-10).    
Nuclear medicine examinations play a well-established role in the diagnostic algorithm of the 
different paediatric nephro-urological conditions. However, long-term studies on their 
prognostic value are desperately required. For example, we still don’t know the risk of long-
term complications (hypertension, chronic renal failure, complications in pregnancy) of one, 
two, three, or multiple and bilateral renal scars. We can determine the function and drainage 
of a hydronephrotic kidney with a PUJ anomaly and we currently know that less than 40% of 
these need surgery to prevent deterioration of renal function; however, we still need to find a 
reliable way to identify those kidneys at risk of losing function if left untreated. We can 
accurately perform an acute DMSA study during a febrile UTI to determine whether the renal 
parenchyma is involved, but we don’t know whether it is possible to avoid a catheter 
cystogram in a child with a normal acute DMSA.  
This article reviews the practice of dynamic and static renal scintigraphy and its clinical 
applications in the paediatric population. In addition, a section on the different clinical 
conditions has been added to present the scintigraphic techniques in clinical context, in 
comparison to the other available radiological examinations. This demonstrates how 
combining these imaging modalities can contribute to the patient’s overall management. 
 
Patient Preparation  
Preparation for the procedure starts during the clinic appointment where the reason for 
requesting the investigation and the examination itself are explained to the parents/child. 
Once a request form has been generated a nuclear medicine practitioner assesses the 
clinical data supplied by the referrer and justifies the medical exposure to radiation (in the 
UK under the Ionising Radiation (Medical Exposure) Regulations, - IR(ME)R - Employer’s 
Procedures). As part of the justification process, the clinical history (including information 
related to the structural renal abnormalities that may result in the need for additional views), 
ultrasound data and previous radionuclide imaging should be reviewed. The importance of 
the justification process cannot be emphasized enough, as young children are much more 
sensitive to radiation than adults and all alternative diagnostic tests yielding equivalent 
information with less or no radiation burden should have been considered.  
The parent/child should receive an appointment letter well in advance of the day of the 
examination containing detailed information on the procedure, including the waiting time 
between tracer injection and image acquisition, the probable duration of the scan and the 
need for adequate oral hydration of the child before getting to the department. Hydration 
should take into account that an increased oral intake of fluids might be needed in hot 
weather and this should also be briefly explained to the family in the clinic (11, 12).  
A co-operative child should be encouraged to empty his/her bladder before the injection to 
reduce the need to void during the acquisition; this is essential for diuretic studies since a full 
bladder may delay upper tract emptying (11-13). If the test involves administration of 
furosemide or bladder catheterization these additional interventions should be fully explained 
as part of the informed consent process. 
On the day of the test, as well as throughout and after completion of the examination, the 
parent(s) and child should feel that their emotional and physical needs have been 
considered in a friendly departmental environment and with the teamwork of trained staff, 
including booking staff, receptionists, nurses and technicians / radiographers. The injection 
room and the gamma camera room should be uncluttered, welcoming, and give the 
impression of a safe environment for both child and parent. This can be achieved by mural 
and gamma camera decorations, the availability of toys for different age groups, small 
rewards (stickers) for cooperative behaviour, books, warm lighting, music and video 
projection capabilities that can be successfully used to distract the child and ensure his/her 
cooperation (11). Departmental staff should have a positive and friendly attitude towards the 
child and parent, making them feel actively involved, reassured and part of the team. The 
child should remain the central focus throughout the entire procedure, but the parent should 
be made aware that he/she offers the best form of comfort and security for the child and 
his/her cooperation can greatly contribute to the success of the examination (11). 
Anaesthetic cream can be applied to relieve the discomfort of the tracer injection, and the 
60-minute wait for the cream to have its effect can be used to ensure good hydration. When 
necessary, an ultrasound can be performed during this interval time. Tracer injection can be 
performed either through a cannula (which also allows the administration of furosemide 
during dynamic renal scintigraphy) or a fine butterfly needle (gauge 23-25 according to 
child’s age). Regardless of the chosen access method, great care should be taken when 
injecting the tracer to avoid extravasation. Administration of radioactivity beyond what is 
essential should be avoided and the amount of radiopharmaceutical to be injected should be 
optimized to give the desired diagnostic information at the cost of minimal radiation burden. 
Recommendations on administered activities for a number of paediatric nuclear medicine 
examinations have recently undergone harmonization by the European and NA societies. 
Calculation of the injected activity is now straightforward either through the EANM and/or 
SNMMI website or the EANM Dosage Card Calculator (14, 15). 
Drug sedation is very rarely used, as adequate preparation, analgesia, environmental 
distractions and team communication with the parent(s) and child help reduce anxiety and 
assist in obtaining adequate immobilization of the child during the procedure (13, 16). 
Sandbags, Velcro straps on either side of the child or a vacuum cushion can also be used as 
external aids for comfortable, yet effective, immobilization. Many of the pitfalls and limitations 
encountered in paediatric radionuclide studies can be avoided by gaining the patient’s and 
family’s cooperation, limiting the child’s movements (by employing distraction techniques 
and immobilisation devices) and using an optimal technical setup for image acquisition (17).  
 
These factors, combined with the full integration of the radionuclide study with 
complementary radiological investigations, will result in a complete morpho-functional 
assessment of the paediatric renal tract, thus aiding clinical management. 
 
 
Static Cortical Renal Scintigraphy 
The European procedure guidelines for Tc-99m-DMSA renal scintigraphy were initially 
published in 2001 and updated in 2011, while similar NA guidelines were initially published in 
1997 and updated in 2003 (currently version 3.0) (5, 7). Tc-99m-DMSA scintigraphy is 
currently the investigation of choice in the assessment of renal parenchymal integrity, and 
provides the most reliable information on differential renal function. Tc-99m-DMSA is used 
for the detection of focal renal parenchymal abnormalities, acute pyelonephritis, post-
infective renal sequelae, renal congenital anomalies (duplex kidney, hypoplastic or 
dysplastic kidney, horseshoe kidney and crossed-fused renal ectopia), and for confirmation 
of a non-functional kidney, such as the multicystic dysplastic kidney (5, 18, 19).  
Tc-99m-DMSA is bound to plasma proteins, cleared from the blood stream by tubular 
absorption and retained by the renal cortex. Renal uptake is dependent on renal blood flow, 
glomerular filtration and megalin/cubilin-mediated endocytosis in the proximal tubule from 
the glomerular filtrate (20, 21). The NA and European dose harmonization process 
recommends a minimum administered activity of 18 MBq (0.49 mCi), gradually increasing it 
in older children according to body weight (EANM Dosage Card Calculator) (14, 15).   
Optimum quality images are acquired at 2-3 hours after tracer injection, when the renal 
cortex has taken up 40%–65% of the injected radiopharmaceutical. Late images (between 4 
to 24 hours) may be useful for quantitation of split renal function when some tracer still 
remains within a dysplastic renal collecting system, thus interfering with the evaluation of the 
split renal function. Images should be acquired with the child in a supine position, as close to 
the collimator surface as possible (ideally on a customized perspex table), to improve image 
quality. Posterior and posterior oblique views (additional anterior views for horseshoe or 
ectopic pelvic kidneys) should be acquired using a low energy, high-resolution or ultra-high-
resolution (+/- pinhole) collimators. Pinhole collimators can improve image resolution and 
contribute to better detection of renal scarring; however they can distort anatomy and 
lengthen acquisition time, with the potential of image degradation by motion artefacts. 
In an older and co-operative child, the European and NA guidelines recommend acquiring at 
least 300,000 - 500,000 counts (or a 600-second image) for the posterior view, and at least 
350,000 counts (or a 600-second image) for the posterior oblique views. For younger and 
less co-operative children the count number can be reduced, with at least 250,000 counts (or 
a 600-second image) acquired for the posterior view and 200,000 counts (or a 600-second 
image) for the posterior oblique views. The acquisition matrix should be 128 × 128 or 256 × 
256. If pinhole views are required, the guidelines advocate 100,000 - 150,000 counts for 
better detection of small cortical defects. In the majority of cases high-quality static planar 
images are sufficient for an accurate diagnostic assessment, but a SPECT acquisition, with 
the possible addition of a low dose CT (where such a scanner is available), can be useful in 
complex cases, such as crossed-fused renal ectopia and complex renal stones (22, 23). 
Recent studies have suggested Tc-99m-DMSA scintigraphy for predicting dilating vesico-
ureteral reflux (VUR) in young children with febrile urinary tract infection but so far only 
limited (and sometimes conflicting) data is available in the literature (24-29). 
Data processing and reporting steps are generally straightforward, but can sometimes be 
challenging in duplex or horseshoe kidneys. Regions of interest (ROIs) are drawn around 
each kidney, with a further ROI defined for background subtraction. In children with normal 
kidney size and position, a reliable background-corrected differential renal function is 
calculated using the arithmetic mean from the posterior view, while in children with ectopic or 
very large kidneys the differential function has to be calculated with the geometric mean. 
Horseshoe kidneys are better defined when imaged anteriorly to detect the connecting 
bridge or isthmus of renal tissue anterior to the spine; however, a posterior view should also 
be acquired. 
Image interpretation should consider several pitfalls, such as normal variants (pear-shaped 
kidney, foetal lobulation, kidney axis rotation), ectopic kidneys, crossed-fused ectopia, the 
influence of motion, high background activity, activity in the renal collecting system and 
tracer contamination (17). The DMSA images should ideally be assessed with the benefit of 
renal ultrasound images, if available. 
 
 
Dynamic Renal Scintigraphy 
Over its more than 40 year history, dynamic radionuclide renography has become an 
indispensable technique in the functional assessment of both adult and paediatric nephro-
urological patients. Although initially suffering from significant local variability, the technique 
has been standardised and it has become increasingly popular in the clinical assessment of 
patients with hydronephrosis. The technique and interpretation have been summarized in 
recent guidelines and reviews (1, 30, 31). The most recent (2011) guideline gives 
recommendations for estimating two indicators of renal function: the relative renal clearance 
(differential renal function, DRF) and the renal excretion of the tracer (1). It recommends that 
DRF estimation should be undertaken between 1 and 2 min after tracer injection (with 
appropriate corrections for background and intra- and extra-renal vascular components), 
while renal excretion can simply be evaluated by inspecting the dynamic renal images and 
with tracer transit quantification techniques (32-34). 
Dynamic radionuclide renography is performed using tubular extraction tracers (I-123-
hippuran), Tc-99m- MAG3 and Tc-99m-ethylenedicysteine (Tc-99m-EC), or Tc-99m-DTPA, 
the only glomerular filtration-dependent radiopharmaceutical. As tubular tracers have greater 
renal extraction than Tc-99m-DTPA (resulting in improved kidney-to-background ratio), they 
are preferred for DRF estimation and indirect cystography in children. Tc-99m-DTPA is 
preferred when glomerular filtration rate (GFR) estimation (with blood sample analysis) is 
required (1). 
The most commonly used radiopharmaceutical is Tc-99m-MAG3, a highly protein-bound 
agent that is removed from the plasma by uptake in the proximal renal tubules (35-37). Its 
renal extraction fraction is 40%-50%, more than twice that of Tc-99m-DTPA, making it an 
excellent clearance agent for patients with suspected obstruction and impaired renal function 
(21, 37). The clinical indications for the procedure include all uropathies that require 
evaluation of drainage (pelvi-ureteric and vesico-ureteric stenosis, bladder outlet obstruction, 
bladder dysfunction, complicated duplex kidneys, renal functional assessment post-trauma, 
asymmetrical renal function, chronic pyelonephritis – with an indirect cystogram performed at 
the end of the renogram - and renal transplantation) (1, 2). The recommended administered 
activities have not been fully harmonized – while the EANM Dosage Card Calculator 
recommends 15 MBq (0.41 mCi) minimum injected Tc-99m-MAG3, the NA guidelines 
suggest a minimum of 19 MBq (0.5 mCi) or, in some practices, 37 MBq (1 mCi) (2, 14). The 
effective dose to a 5-year-old child is < 1 mSv (0.54–0.82 mSv for Tc-99m-DTPA, 0.20 - 0.38 
mSv for Tc-99m-MAG3 and 0.41 - 0.7 mSv for I-123-hippuran) and reduction of injected 
activity is advocated if renal function is impaired (38-40). 
Good hydration is essentially for a good quality dynamic study. Some guidelines recommend 
intravenous hydration (2), whilst in other parts of the world oral hydration, starting a few 
hours prior to the renogram, is considered sufficient (1).  
Image acquisition is performed with a constant 10 or 20 second frame rate (10 second 
frames for quantification), up-facing low energy general purpose collimator, 128 × 128 and 
word (or byte) mode, with zoom adjusted to patient size and including the heart for 
processing purposes. Post-micturition views (at the end of the study and 50-60 minutes post-
tracer injection) are essential and they will help distinguish between a dilated non-obstructed 
and an obstructed renal tract. Although widely used in NA centres, bladder catheterization is 
not advocated by the European guidelines (2). The minimum recommended duration of the 
study is 20 minutes.  
Evaluation of split renal function 
The evaluation of split renal function has been standardised (32). In the processing step, the 
regions of interest (ROIs) should be generous, drawn on a summed image and 
encompassing the entire kidney to avoid excluding some renal activity (41-43). Background 
correction using rectangular, elliptical or peri-renal ROIs should be performed on all images / 
renogram curves, and the cardiac ROI, needed for quantification, should cover the hottest 
pixels over the heart on the very first two or three frames (1). A 2 – 3 minute summed image 
of all the frames during the clearance or uptake phase should be created and the DRF 
assessed visually on the images and uptake curves, as well as calculated using either the 
integral method or the Patlak-Rutland plot method (32, 41, 44-48).  
The integral method calculates the mean value of the area under the background-subtracted 
renogram curves during a 1-2 minute period. This method has been shown reproducible and 
accurate in normal volunteers, with a difference of more than 5% representing a significant 
change (41).  
The Rutland-Patlak plot is a graphic representation of the split renal function; the slope of the 
fit curve represents the relative function of each kidney. In theory, this method is more 
accurate than the integral method because of the added correction of the intrarenal vascular 
component. However, it is also more prone to statistical errors in conditions with increased 
background activity, such as infants with immature renal function and patients with chronic 
kidney disease. 
The evaluation of the split renal function using two independent methods constitutes a good 
quality control; both methods should give the same result (within 5% difference). 
 
Evaluation of drainage 
The furosemide test was introduced in the late 1970s to help in differentiating between 
urinary outflow obstruction and urinary stasis due to a baggy collecting system (49). 
Furosemide is injected at 20 minutes if the dynamic images show slow drainage: a dilated 
non-obstructed renal pelvis usually shows response with significant drainage, whilst an 
obstructed renal pelvis shows poor response to the diuretic.  More recently, the “F0” 
technique has been introduced, with the diuretic injected together with the radiotracer: this 
shortens the time of acquisition and results in better drainage at the end of the renogram. 
Administration of furosemide 15 minutes prior to tracer injection is another possible 
technique, which allows starting the renogram under the full effect of furosemide (50-54). 
Recommended furosemide doses are 1mg/kg i.v.in infants and 0.5 mg/kg in children above 
the age of 1 year (20 mg maximum dose). One of the pitfalls related to drainage is the 
presence of a full bladder at the end of the renogram. Therefore, the insertion of a bladder 
catheter during the test has been recommended, especially in North America (55). The 
European guidelines recommend instead the acquisition of a post-micturition view, after the 
child has been in upright position for at least 15 minutes and has emptied the bladder, 
acquired in the same way as the dynamic renography, so that it can be compared with it (1).  
The evaluation of drainage has been standardised, with several functional parameters being 
proposed. The Output Efficiency (OE) represents the amount of activity that has left the 
kidney, expressed in a percentage of what has entered the kidney (56). The Normalised 
Residual Activity (NORA) is a parameter inversely correlated with OE and describes the 
amount of activity remaining in the kidney at the end of the renogram (57). These 
parameters are independent on the level of differential function and can be calculated at the 
end of the renogram as well as on the delayed post-micturition views. 
For a long time, drainage has been estimated on the basis of the slope of the furosemide 
curve, a long T-half reflecting obstruction and a short T-half indicating good urinary outflow. 
This method is accurate only when drainage is good, but fails to differentiate poor drainage 
due to obstruction from poor drainage due to a dilated non-obstructed collecting system.  
Lack of protocol standardization (especially for post-micturition images), tracer 
extravasation, motion, high background activity, bladder status, poor renal function, degree 
of renal pelvic dilatation, can all pose interpretation challenges (17). 
 
Renal Immaturity 
When evaluating newborns and infants, nuclear medicine practitioners should recognize 
normal renal immaturity and its effect on the renal handling of radiotracers (58). The 
glomerular filtration rate (GFR) per unit of surface area in the newborn is approximately 30% 
of the adult rate. Depending on renal maturation, renal uptake of tracers may be lower in 
newborns than in older children and adults. In addition, intrarenal transit time and excretion 
of these tracers may be slow at this age. Background may be high throughout the study, 
reflecting slow plasma clearance of the tracer. 
 Radionuclide Micturating Cystography  
Direct radionuclide cystography (DRC) is a catheter cystogram that entails administration 
of a small amount of Tc-99m-pertechnetate together with saline into the bladder. It is 
indicated in non-toilet trained boys (usually less than 3 years of age), when a reassessment 
to look for persistent VUR after endoscopic or surgical treatment is required, once a baseline 
radiological MCUG has excluded posterior urethral valves. In girls, less than 3 years of age, 
it is utilised when the DMSA scan is abnormal and an US shows a dilated ureter and/or 
pelvis. It can also be used in the diagnosis of familial reflux, or in the serial evaluation of 
bladder dysfunction (neuropathic bladder) for VUR (3, 4, 6).  
As VUR is an intermittent phenomenon and it may only occur in the filling phase of the 
bladder, the advantage of DRC is that both the filling and micturition phases can be studied, 
increasing the chances of detecting VUR (59-61). DRC may be undertaken in any child, but 
it has a limited role in low lying or ectopic kidneys with ureteric dilatation. The main 
disadvantage is that it requires bladder catheterisation (with all its associated risks / 
discomforts): this should be performed by an experienced operator under strict aseptic 
conditions and antibiotic prophylaxis (3). 
Imaging acquisition requires the administration of 20 – 40 MBq of Tc-99m-pertechnetate in 
500 ml saline through the catheter over 10 minutes until full bladder capacity is reached and 
then the child is allowed to void. Dynamic posterior view frames are acquired at maximum 5 
seconds per frame using a general-purpose collimator and 64 x 64 or 128 x 128 matrix. The 
radiation burden from the procedure is favourable compared to MCUG, although a recent 
publication has reported a lower radiation exposure from the fluoroscopic procedure when 
using state-of-the-art equipment and frame grab techniques (62). 
Indirect isotope cystography (IRC) is a completely physiological test in toilet trained 
children used for the detection and follow-up of VUR and the assessment of the effect of a 
full and empty bladder on the drainage from dilated upper tracts (4). The advantage of this 
technique is that it allows a complete functional assessment of the urinary tract (including 
renal parenchymal integrity, split renal function, drainage, timing and completeness of 
bladder emptying), it has a low radiation burden and it does not require bladder 
catheterization, which can be physically and emotionally traumatic for the patient.  
The patient sits on a commode with the gamma camera centred posteriorly over the region 
of the bladder and kidneys. The patient voids into a urinal, a bedpan, or a jug. Precautions to 
reduce contamination of the equipment and the room must be taken. Recording is begun 
when the patient is ready to void and continues until the end of voiding. If the child has failed 
to void on the first attempt, or has voided incompletely, another cystogram can be acquired 
later on, until the bladder is empty, or VUR has been demonstrated. Repeated acquisitions 
increase the sensitivity for VUR.  
 
The most common pitfalls in radionuclide micturating cystography are too early micturition, 
before the radiographer has commenced images acquisition (often because the child is not 
really toilet trained), and a dilated renal collecting system with persisting urinary stasis from 
the immediately previous dynamic renography (17). These can be mitigated by performing 
IRC in children who are continent and by furosemide administration before the start of the 
first IRC to clear the upper tracts (17). Knowledge of the expected functional bladder 
capacity is useful for evaluation of VUR in children.	
	
In the absence of bladder pathology such as bladder exstrophy-epispadias complex, the 
expected bladder capacity for age can be estimated by the formula 30 + (30 x age in years) 




CLINICAL APPLICATIONS OF NUCLEAR MEDICINE IN PAEDIATRIC NEPHRO-
UROLOGY 
 
URINARY TRACT INFECTIONS AND VESICO-URETERIC REFLUX 
Background 
Approximately 2% of males and 8% of females will develop a urinary tract infection (UTI) at 
some point. Most UTIs in males occur at <3 months of age with prevalence 10 times less in 
circumcised males versus uncircumcised males in this age group. After one year of age, 
most UTIs occur in females.  
 
Symptomatic UTI must be differentiated into upper tract infections, with lesions of the 
kidneys (acute pyelonephritis and pyelitis), and lower tract infections (acute cystitis). Upper 
UTI usually presents with high fever, flank pain or tenderness, malaise, irritability, 
leukocytosis, and bacteriuria, but there may be no clear indication that there is renal 
parenchymal infection. Lower UTI presents with voiding symptoms. However, it is often 
impossible to differentiate them or even to diagnose UTI, particularly in babies (65).  
 
Primary goal in the diagnosis of UTI and in the subsequent evaluation of the predisposing 
factors is to reduce the incidence of recurrent UTI and prevent acquired renal damage. 
 
Imaging in UTI  
The purpose of imaging is to detect pathological malformations and/or risk factors that, if not 
diagnosed and managed appropriately, might lead to additional infections and on-going 
parenchymal damage. Ultrasound, MCUG and Tc-99m-DMSA scan are the core imaging 
examinations utilised. However, the use of these imaging techniques is variable with 
different approaches.  
 
Ultrasound 
Renal ultrasound can define kidney shape, length, echogenicity, and the presence of 
dilatations. Ultrasonography can also describe the bladder volume, bladder wall thickness 
and renal and bladder calculi, ureteric abnormalities and adjacent pathology (such as 
collections). The disadvantages are the poor detection rate of parenchymal defects and 
VUR. In one series of children with their first febrile UTI (66), 88% of patients had normal US 
findings (11.5% had dilated urinary tract and 0.3% renal calculi). 
 
Renal cortical scintigraphy 
 
“Acute” DMSA: A DMSA scan performed during the acute phase of a UTI can confirm the 
presence of acute pyelonephritis. The diminished uptake of Tc-99m-DMSA in areas of acute 
inflammation probably reflects both focal tubular cell dysfunction and ischaemia (67). DMSA 
scanning does not differentiate old from new lesions unless a previous examination exists.  
Acute DMSA imaging will confirm the diagnosis of acute pyelonephritis in patients with 
equivocal symptoms. The advantage of this approach is that in patients with normal acute 
DMSA there is no probability of developing renal scarring. The sensitivity of Tc-99m-DMSA 
scintigraphy for the early diagnosis and localization of acute pyelonephritis reaches over 
90% (68).  
 
“Late” DMSA: If treated appropriately within 48 hours, acute pyelonephritis may resolve 
completely and scintigraphic images typically would become normal within 4–6 months. 
Alternatively, without adequate and early antibiotic treatment, a permanent cortical scar may 
develop. A mature cortical scar is usually associated with contraction and apparent loss of 
volume of the involved cortex. This may manifest as cortical thinning on ultrasound, 
flattening of the renal contour, or a wedge-shaped defect. The scintigraphic pattern of a 
maturing scar on DMSA varies according to the severity of the UTI, the location of the lesion, 
the age of the patient, as well as the rate of growth of the surrounding normal renal tissue. 
The guidelines issued by the National Institute for Health and Clinical Excellence (NICE) 
recommend a DMSA scan in children with recurrent or atypical UTIs, 4-6 months after the 
infection (69). Some investigators recommend renal scintigraphy 6-12 months after the first 
febrile UTI to detect the formation of scarring, which would require follow up (70, 71). 
 
The prognostic value of renal scars needs to be further evaluated. A study from Sweden 
showed that a cohort of children with renal scarring followed up for 1—26 years had no 
increased likelihood of developing hypertension in comparison to the general population 
(72). However, a recent study showed increased blood pressure in a cohort of patients with 
normal renal function and UTI associated renal damage (73). Other studies have reported a 
significantly increased risk of hypertension and chronic kidney disease in children with 
bilateral scarring (73-75).  
 
Although ultrasound is the favoured imaging method in children, MRI, and occasionally CT, 
may have a role when intrarenal abscesses are suspected or when there is a delayed 
response to antibiotic treatment (76, 77). 
 
Vesico-Ureteric Reflux 
Vesico-ureteric reflux (VUR) refers to the retrograde flow of urine from the bladder into the 
ureter and, usually, into the collecting system of the kidney. In most individuals, VUR results 
from a congenital anomaly of the vesico-ureteric junction, whereas in others it results from 
high-pressure voiding secondary to posterior urethral valves, neuropathic bladder or voiding 
dysfunction. Its management is one of the most controversial topics in paediatric urology. 
 
The clinical importance of VUR consists in its association with pyelonephritis and its 
contribution to reflux-related renal scarring. Vesico-ureteric reflux is a not an uncommon 
urological anomaly in children, with an incidence of nearly 1%. However, the incidence of 
VUR is much higher among children with UTIs (30-50%, depending on age). Among all 
children with UTIs, boys are more likely to have VUR than girls (29% vs. 14%); boys also 
tend to have higher grades of VUR diagnosed at younger ages, although their VUR is more 
likely to resolve (78). 
 
Grading of reflux is based on the work of the International Reflux Study Group and includes 
VUR from grade I–V (Fig.1). Not all types of VUR carry the same risk of contributing to renal 
scarring. For example, dilating VUR will increase the risk of developing acute pyelonephritis 
and renal scarring. A significant percentage (10 – 40%) of children with symptomatic VUR 
have evidence of renal scarring, resulting from either congenital dysplasia and/or acquired 
post-infectious damage, which may have a negative impact on growth and general wellbeing 
(79).   
 
High grade VUR is associated with a higher risk of renal scarring and recurrent UTIs (80). 
Lower grade VUR is associated with a lower risk of renal scarring and may vary from 
examination to examination. VUR varies also with bladder volume, voiding or filling, patient 
position, and level of anxiety. Renal scarring occurs in approximately 10% of children with 
prenatal hydronephrosis and VUR (81, 82), whereas in patients with lower urinary tract 
dysfunction scar rate may increase up to 30% (83). Renal scarring may adversely affect 
renal growth and function, with bilateral scarring increasing the risk of chronic kidney 
disease. Follow-up studies have shown that 10-20% of children with chronic pyelonephritis 
and VUR develop hypertension or end-stage renal disease (84). 
 
The spontaneous resolution of VUR is dependent on age at presentation, sex, grade, 
laterality, mode of clinical presentation and renal tract anatomy (85). In several Scandinavian 
studies, the complete resolution rate for high-grade VUR has been reported in excess of 
25%, which is higher than the resolution rate for VUR detected after infancy (86). 
 
High grade VUR, age at diagnosis and male gender have been shown to be risk factors for 
renal parenchymal damage. In this group of patients it is mandatory to discover reflux early 
to prevent renal damage (87). 
 
Management of a Patient with VUR 
Controversy persists over the optimal management of VUR, particularly the choice of 
treatment (observational, medical, endoscopic or open/laparoscopic surgical), and the timing 
of treatment. The main goal in management is the preservation of kidney function, by 
minimising the risk of pyelonephritis. By defining and analysing the risk factors for each 
patient (i.e. age, sex, reflux grade, lower urinary tract dysfunction, anatomical abnormalities, 
and kidney status), it is possible to identify those patients with a potential risk of UTIs and 
renal scarring. 
 
There are two main approaches to the management of VUR: conservative and surgical. In all 
patients with secondary VUR, management of the underlying anomaly should be considered 




The conservative approach includes watchful waiting, intermittent or continuous antibiotic 
prophylaxis, and bladder rehabilitation in those with lower urinary tract dysfunction. The 
objective of conservative therapy is prevention of febrile UTI and it is based on the 
understanding that VUR resolves spontaneously, mostly in young patients with low-grade 
reflux. Resolution is nearly 80% in VUR grades I and II and 30-50% in VUR grades III-V 
within 4-5 years of follow-up (85). Furthermore, VUR does not damage the kidney when 
patients are free of infection and have normal lower urinary tract function. There is no 
evidence that small scars can cause hypertension, renal insufficiency or problems during 
pregnancy (72). Circumcision during early infancy may be considered as part of the 
conservative approach, as it is effective in reducing the risk of infection in normal children 
(90). 
 
Regular follow-up with ultrasound imaging is part of the conservative management. In all 
cases of febrile breakthrough infections despite prophylaxis, intervention should be 
considered.  
 
Recent prospective randomised controlled trials have shown that the role of prophylaxis in 
children with no VUR or with grade I or II VUR is questionable, as the rate of recurrent 
symptomatic UTIs was similar in the group with prophylaxis and in the group with no therapy 
(80, 91-93). For children with VUR grade III to V, who have a much higher rate of recurrent 
UTI (80, 94-96) prophylaxis would be appropriate, particularly in girls. There is no data on 
the optimal duration of prophylaxis. 
 
Surgical correction of VUR 
Endoscopic treatment: VUR can be corrected by endoscopic injection of a bulking agent at 
the VUJ or by surgical re-implantation.  
 
The sub-ureteric injection of bulking materials is currently the first therapeutic option in 
children with VUR and recurrent infections. The injected agent elevates the ureteral orifice 
and the distal ureter, so that coaptation is increased. This results in narrowing of the lumen, 
which prevents reflux of urine into the ureter, while still allowing its antegrade flow. With the 
availability of biodegradable substances, endoscopic sub-ureteric injection has become an 
alternative to long-term antibiotic prophylaxis and surgical intervention.  
 
The reported resolution rate is 83% for endoscopic therapy after a single injection (American 
Urological Association guidelines (97). Imaging with a MAG3 dynamic renogram and an 
indirect cystogram is helpful at follow up, usually 6-9 months after the procedure, to 
demonstrate the resolution of VUR and to show possible complications (most commonly 
obstruction at the VUJ).  
 
Ureteric re-implantation: Surgical treatment of VUR in the form of open or 
laparoscopic/robot assisted ureteric re-implantation is considered whenever endoscopic 
treatment has been unsuccessful or is inappropriate. It is an alternative in children older than 
1 year of age, or in patients with persistent VUR after 2–3 years of follow-up, in patients in 
whom decreasing renal function is observed, or in patients presenting with recurrent UTI 
despite adequate antibiotic therapy. 
 
Imaging VUR 
Imaging is the basis of diagnosis and management of VUR. The aim in detecting VUR and 
initiating a prophylactic treatment is to prevent long-term complications (98-101).  
 
Micturating Cystogram (MCUG) is the most widely used radiological examination for the 
study of the lower urinary tract and especially of VUR. It is the only method that allows 
precise grading of VUR and the detection of intrarenal reflux (102-106). MCUG should 
always be performed in infant boys, to exclude posterior urethral valves, but less so in girls. 
The main disadvantages of the technique are the risk of infection, the need for retrograde 
filling of the bladder and the possible deleterious effect of radiation on children. In recent 
years, tailored low-dose fluoroscopic MCUG has been used for the evaluation of VUR in girls 
in order to minimize radiological exposure. 
 
Direct Radionuclide Cystogram (DRC) is a sensitive technique to diagnose VUR. The 
advantages of DRC are the extremely low radiation dose and the ability to continually screen 
for VUR during both the bladder filling and emptying. This unique ability of the DRC is the 
reason for its high sensitivity in picking up reflux, with higher sensitivity and higher temporal 
resolution than MCUG (107). The disadvantages include the insertion of a bladder catheter 
and poor anatomical detail. As mentioned previously, this technique is used in the follow up 
of non-toilet trained boys who have already had a MCUG to exclude posterior urethral 
valves, and in non-toilet trained girls when detailed anatomy of the bladder and ureters is not 
required.  
 
The Indirect Radionuclide Cystogram (IRC) represents an attractive alternative to 
conventional cystography, as previously noted, especially when following patients with 
reflux, because of its lower dose of radiation and lack of catheterisation. Disadvantages are 
poor image resolution and difficulty in detecting lower urinary tract abnormalities (108). 
 
Imaging strategies in children with UTI and VUR 
The use of diagnostic imaging tests in a child with UTI is still a matter of controversy. In 
much of the literature considerable attention has been placed on the diagnosis of VUR, with 
the conclusion that the only useful examination after a first febrile UTI is a MCUG (66). Most 
researchers would agree that detecting VUR with associated dilatation is important, given 
the increased risk of scarring and the ability to intervene medically and surgically in this 
condition (94, 95). Because the presence and the severity of VUR can be reliably 
determined only by MCUG, these groups advocate performing MCUG in all children after a 
first febrile UTI (66). 
 
Alternatively, the so-called “top down” approach is adopted in many countries. This imaging 
strategy aims to reduce the number of MCUGs. A DMSA scan is performed during the acute 
phase of the UTI. If this is positive, the chance of dilating VUR is high and a MCUG will be 
performed. If the acute DMSA is negative, a MCUG is not performed. Some studies have 
shown a strong correlation between clinically relevant VUR with dilatation and abnormal 




Other groups feel reluctant to adopt the “top down” approach, because the result of an acute 
DMSA would not change the duration and the form of delivery of antibiotic therapy. Previous 
studies have shown that longer courses (7 to 14 days) of intravenous antibiotic therapy, 
compared to shorter courses (3 to 4 days) followed by oral treatment (115-117), resulted in 
no difference in rates of subsequent renal damage, irrespective of the duration of therapy. 
Oral antibiotics have been compared to a regimen including three days of intravenous 
cefotaxime followed by 11 days of oral cefixime alone, with no difference in outcome (118).  
 
In 2007 the National Institute for Health and Clinical Excellence (NICE) in the UK published a 
set of guidelines on urinary tract infections (69). The main philosophy of these guidelines is 
to concentrate imaging studies in the child clinically at risk of developing renal damage 
following an episode of infection. Children with a non-febrile UTI do not need any initial 
imaging of their urinary tract. Children with recurrent attacks of lower UTI might need 
imaging that focuses on bladder function. Children with febrile UTI can be divided into two 
groups: children at high risk and at low risk of developing renal damage. If the UTI is atypical 
or they have recurrent UTI, the children fall in the high risk category and need an US 6 
weeks after the UTI and a DMSA scan at 4-6 months. High-risk children under 6 months of 
age require a renal tract ultrasound during the acute infection followed by a DMSA 4-6 
months after infection and a MCUG. Children between 6 months and 3 years of age do not 
require any imaging if they respond to antibiotic treatment within 48 hours and are classified 
as low risk. Low risk children need no imaging if they do not develop a second infection 
(which brings them into the high risk group). A MCUG is not routinely performed unless there 
is evidence of dilatation on US, poor urine flow, non-E. Coli UTI, or family history of VUR. In 
children older than 3 years of age, a DMSA scan is performed at 4-6 months only if the child 
has had recurrent UTI (69).   
 
The NICE guidelines have been criticised by studies that show that a significant number of 
abnormalities, especially high grade VUR, may be missed if the guidelines are followed 
(119-121); the authors state that the NICE guidelines should be used with full awareness of 
their limitations. 
 
The Italian Renal Infection Study Group has proposed an alternative imaging approach in 
young children with a first febrile UTI (71). Their results in a group of 300 children aged <2 
years with a first febrile UTI suggest that the benefit of performing US at diagnosis and acute 
DMSA is minimal. They recommend a specific role for US, namely for children in whom it 
was not performed ante-natally, those with poor response to antibiotics, and those with 
complicated or recurrent infections. A good quality US during the prenatal screening will 
detect the small proportion of congenital abnormalities. In their study, the MCUG yielded 
positive results for VUR in only 22% of children, with only 4 children showing grade IV or V 
VUR. They concluded that the use of MCUG in 300 children to detect 4 cases of severe 
VUR, which could be diagnosed after a second UTI, is not justified. The acute DMSA was 
positive in 54% of cases and showed changes compatible with acute pyelonephritis. 
However, this did not change management as no significant difference has been 
demonstrated between administering antibiotics intravenously or orally (122). Therefore, the 
authors question the value of routinely performing acute DMSA scans in children with a 
febrile UTI. This study emphasises the importance of renal scarring, rather than VUR, as the 
main prognostic factor for a patient’s outcome after a UTI. The detection of VUR was poorly 
correlated with subsequent renal scarring in children with a first febrile UTI, with no evidence 
that its diagnosis improved outcomes or warranted alteration in management. Those patients 
with scarring on late DMSA (done at 12 months after the UTI) and those with recurrent 
febrile UTI should be considered for further investigation. The impact of such renal scars on 
the development of long-term complications has yet to be determined. 
 
Conclusion: Controversy still exists in imaging and management of UTI. Long-term cohort 
studies with sufficient statistical power that establish the prognostic significance of renal 
scarring are needed.  Ultrasound of the kidneys and bladder is always the first line 
investigation to assess dilatation and secondary signs of reflux such as intermittent collecting 






ANTE-NATALLY DIAGNOSED HYDRONEPHROSIS 
Ante-natally diagnosed hydronephrosis may have several causes, of which the most 
common is the pelvic-ureteric junction anomaly (PUJA) (123).  
 
PUJ ANOMALY 
Dilatation of the upper urinary tract still presents a significant clinical challenge in 
determining which patient may gain benefit from therapy. Due to the widespread use of 
ultrasonography during pregnancy, antenatal hydronephrosis is often found. The challenge 
in the management of dilated upper urinary tracts is to decide which child can be observed, 
which one should be managed medically and which one requires surgical intervention.  
 
Diagnostic Imaging – Definition of Obstruction 
An ante-natally diagnosed hydronephrosis is normally monitored with ultrasound after birth.  
On ultrasound, the antero-posterior diameter of the renal pelvis, calyceal dilatation, kidney 
size, thickness of the parenchyma, cortical echogenicity, ureters, bladder wall and residual 
urine are assessed. The sonographic diagnosis of a PUJ anomaly depends on the 
demonstration of a dilated renal pelvis in the absence of any dilation of ureter or bladder. It 
should particularly be suspected when moderate (10-15 mm) or severe (>15 mm) dilation is 
seen (124). Hydronephrosis has been classified in different grades (Fig.2).   
 
The pathological basis of the PUJA is an abnormal muscle arrangement with an anomalous 
collagen collar at the level of the PUJ. In vast majority of cases an ante-natally diagnosed 
hydronephrosis resolves spontaneously, as a manifestation of physiologic change during 
development (125, 126). 
 
Not all children with antenatally diagnosed hydronephrosis require assessment with dynamic 
renography. This is reserved for children with a moderately to very dilated renal pelvis 
(>12mm in AP diameter) and with calyceal dilatation. For an infant, 6 weeks of age is 
generally accepted as a reasonable time to undergo first renal scintigraphy. As mentioned 
earlier, Tc-99m-MAG3 provides superior diagnostic images and is the agent of choice for 
renal scintigraphy in children (127). 
 
It has been noted that the vast majority of cases of ante-natally diagnosed hydronephrosis 
resolve spontaneously (125, 128). In approximately 25% - 30% of cases the PUJ anomaly in 
an asymptomatic patient causes a significant resistance to urinary outflow, with backward 
pressure on the renal tubules. This causes stretching of the parenchyma and, in the long 
run, loss of kidney function if the condition is left untreated (128). These are the kidneys that 
get obstructed.  
 
Unfortunately this definition of obstruction is retrospective and unhelpful. Contrary to the 
adult practice where an obstructed kidney declares itself with symptoms, the vast majority of 
children with ante-natally diagnosed hydronephrosis are asymptomatic, including the 
majority of those who will develop obstruction to urinary outflow. Therefore, it is difficult to 
clinically identify the kidney at risk.   
 
Slow drainage and urinary stasis at the level of the PUJ does not necessarily mean 
obstruction (129). It may signify a condition of equilibrium, thereby there is a degree of 
resistance to urinary outflow, but not sufficient to cause a fall of renal function; with time and 
with maturation and growth of the excretory system, the PUJ stenosis may resolve. 
Therefore, it is important to consider that the previously widely accepted classification of the 
diuretic renogram curve patterns as no obstruction, indeterminate or obstruction (49, 130) 
has been superseded by a better understanding of the urodynamics. A large renal pelvis 
without significant urinary flow impairment may cause very slow drainage, with no significant 
deterioration in renal function and eventually spontaneous improvement. 
 
In a young child with hydronephrosis, one should not arrive at the diagnosis of obstruction 
based on a single examination. A single study provides only a “snapshot” of a changing 
situation. Serial studies over time provide a better indication of the natural progression of 
renal dilatation and help determine the presence of an obstruction. Future deterioration of 
renal function cannot be predicted solely based on findings of increasing dilatation on 
ultrasound, or a rising curve and/or a low differential function on diuretic scan.  
 
The function of the hydronephrotic kidney will be affected by the severity of the PUJ 
stenosis. High pressure in the pelvi-calyceal system can result in reduced renal blood flow 
and decreased cortical function. In the young, this can be reversed after relief of the urinary 
obstruction. Renal blood flow decreases rapidly with increased pressure in the pelvi-calyceal 
system. This can be reversible for a period of time, but if increased pressure is long-
standing, reduction in blood flow and function can become permanent.  
 
It is usually possible to identify a single site of obstruction at the VUJ or the PUJ, but 
obstruction at both the PU and VU junctions may be difficult to detect. Detection of the level 
of urinary stasis depends on adequate renal function and the presence or absence of 
dilatation of the pelvi-calyceal system and ureter (124).   
 
In studies of hydronephrosis due to a severe PUJ stenosis, the affected kidney paradoxically 
may take up more tracer than the contralateral side (supra-normal kidney). It is thought that 
the kidney with a tight PUJ stenosis develops transiently increased blood flow. Over time, 
renal function in an obstructed kidney will reduce. 
 
Symptomatic obstruction (recurrent flank pain, urinary tract infection) and decreased split 
renal function at initial assessment are often used as absolute indications for surgery.  
The recommendation is to perform an open, laparoscopic or robotic assisted pyeloplasty, 
according to the standardised technique of Anderson and Hynes (131). Open surgery 
remains the management of choice in neonate and young infants compared with a minimally 
invasive approach. In older children, the choice is more controversial but the laparoscopic 
approach continues to gain increasing acceptance. 
Renal scintigraphy may help physicians in the follow up of patients after surgery. 
Scintigraphy is usually performed 6-9 months after pyeloplasty. Young patients with 
moderately impaired differential renal function and patients diagnosed because of symptoms 
may have the greatest likelihood of a functional improvement (132). 
 
The Hydronephrotic Kidney at Risk 
The identification of the hydronephrotic kidney at risk of losing function is still controversial, 
with different approaches to the management of the child (133).   
 
The degree of hydronephrosis in the post-natal period is important. Spontaneous resolution 
takes place in approximately 50% of the cases with mild hydronephrosis, whereas it is much 
less frequent in cases with more pronounced dilatation (134). No intervention is required in 
the majority of cases. It is more likely that the child will need surgery if the renal pelvis 
diameter is greater; however, a convincing demonstration that pyeloplasty is mandatory is 
missing. Some urologists have shown that a dilated renal pelvis may have a protective role 
on the kidney (135). 
 
Decreased split function at initial assessment is often used as an absolute indication for 
surgery, but this has been questioned in a prospective study with conservative follow-up 
(136, 137). Moreover, the overall impression is that improvement does not occur when 
surgery is performed because of initial decreased function. Very different is the sudden 
increase of hydronephrosis during follow up, which indicates imbalance of a urodynamic 
equilibrium and the risk of renal deterioration. 
 
A parameter thought to be diagnostically helpful is the renal cortical transit of the tracer, in 
other words the passage of tracer from the outer cortex to the medulla and collecting 
system. In a normal kidney, a rapid cortical transit is expected in the first minutes of the 
acquisition. It has been suggested that impaired cortical transit of tracer, with absence of 
activity in the subcortical structures of the kidney within 3 minutes of tracer injection, might 
be predictive of a significant improvement of function after pyeloplasty, or might represent a 
high risk of deterioration if surgery is delayed (138-140) (Fig.3a,b). 
 
Conclusion: The identification of the ante-natally diagnosed asymptomatic hydronephrotic 
kidney at risk of losing function is still the main clinical challenge. Slow cortical transit of 
tracer may be a helpful sign but larger studies are necessary to confirm this finding.   
 
	
MEGAURETERS AND VUJ ANOMALY 
Foetal ultrasonography has identified a greater prevalence of megaureter (ureteric diameter 
greater than 7mm), in the general paediatric population than previously though
Megaureters are reported to occur in approximately 23% of neonates noted to have 
antenatal hydro-ureteronephrosis. They occur more often in males and more likely on the left 
side (141). 
Dynamic renography with Tc-99m-MAG3 is indicated to assess the cortical renal function 
and confirm the level of urinary hold up with a full and an empty bladder. It is worth noticing 
that in the case of VUJ anomalies with a dilated renal pelvis, the MAG3 renogram may show 
predominant or exclusive urinary stasis within the renal pelvis, with little or no significant 
urinary stasis within the dilated ureter. In this case, if the ultrasound shows a dilated ureter 
down to the level of the VUJ (and possibly more dilated at the distal end), the diagnosis of a 
megaureter is still likely, even if the dynamic renography has not demonstrated this. This is a 
well-recognized pitfall of renography in this condition (Fig. 4a,b,c). 
 
Only 10-20% of megaureters require surgical treatment, whilst the remainder may be 
monitored conservatively. The characteristic adynamic segment of the distal ureter just prior 
to its insertion into the bladder can either be cut using balloons at cystoscopy, or excised 
with subsequent re-implantation of the ureter.  
 
Non-obstructed megaureters  
Children with asymptomatic megaureters associated with a DRF in excess of 40% may be 
managed conservatively. If a functional study reveals adequate ureteral drainage, low-dose 
prophylactic antibiotics within the first year of life are recommended for prevention of urinary 
tract infections, although there are no prospective randomised trials to evaluate this regimen 
(142). Close follow-up every 3-4 months with ultrasound and antibiotic prophylaxis are 
warranted, especially in cases with significant dilatation (>1cm ureteral diameter) (143, 144). 
Megaureters with grades 0 - 2 hydronephrosis at diagnosis are likely to resolve between 12 
and 36 months of age. Grades 3 - 4 hydronephrosis may take longer to resolve, up to 72 
months (144, 145).  
 
Obstructed megaureters 
In some clinical scenarios surgical management is necessary: increasing hydro-
ureteronephrosis, deteriorating renal function on scintigraphy, recurrent urinary tract 
infections despite antibiotics, or presence of pain, pyonephrosis or stones.    
Traditionally, the surgical management of an obstructing megaureter has been via ureteric 
re-implantation with or without ureteral remodelling. Ureteral re-implantation has good 
results, with a success rate of 90 - 96% (146, 147).  
 
In general, follow-up investigations using ultrasonography and radionuclide imaging are 
carried out between 6 and 9 months after surgery. After the first follow up, prophylactic 






Renal disease associated with hypertension can be caused by conditions that involve the 
renal arteries or the renal parenchyma. Renovascular disease (RVD) is an important but 
uncommon cause of hypertension in children, accounting for about 10% of cases (148-150). 
Renal pathology is the cause of hypertension in over 90% of children after 1 year of age. 
Less frequently, secondary hypertension may be caused by disorders of the endocrine, 
cardiovascular, or nervous systems. Radionuclide renal studies play an important role in the 
evaluation of hypertension in infants and children. 
 
Fibromuscular dysplasia is the commonest cause of RVD in childhood, but other 
associations include neurofibromatosis type 1, Williams’ syndrome, idiopathic hypercalcemia 
of infancy, and vasculitis, especially Takayasu disease. Middle aortic syndrome is a 
morphological pattern in which the abdominal aorta and one or more of its major branches 
are stenosed. This pattern may arise from most of the major causes of RVD in childhood. 
 
In children, especially those with an identifiable underlying cause such as neurofibromatosis 
type 1, arterial involvement tends to be more extensive than in adults. Bilateral disease and 




Non-invasive imaging alone cannot reliably exclude RVD as the cause of paediatric 
hypertension (152, 153), but may confirm or exclude an alternative pathology. Ultrasound is 
a simple first imaging test in a child found to have high blood pressure. It may detect small 
and/or scarred kidneys, renal and adrenal tumors, or hydronephrosis. Doppler studies are 
most useful for the diagnosis of RVD because direct visualization of renal artery stenosis is 
difficult. A normal ultrasound study does not exclude a single renal scar, renovascular 
pathology (especially within smaller intrarenal branches), or a small phaeochromocytoma 
(especially if it is extra-adrenal). If ultrasound has demonstrated Doppler abnormalities 
clearly suggesting RVD, it is most appropriate to proceed directly to angiography. If this is 
not the case then further investigations are focused on confirming or excluding an alternative 
renal cause for the hypertension.  
 
Some of the renal causes of hypertension, such as infarction, scarring, and post-traumatic 
lesions, are readily diagnosed by DMSA scintigraphy. If the ultrasound is normal a DMSA 
scan may reveal focal scarring as an underlying pathology. If both the ultrasound and the 
DMSA are normal, RVD should still be considered and a diagnostic angiogram may still be 
indicated. 
 
Dynamic renal scintigraphy has been utilised in the diagnostic work up of renovascular 
hypertension (154), especially before and after administration of an angiotensin-converting 
enzyme (ACE) inhibitor such as captopril (155-157). Although pre- and post-captopril 
scintigraphy has been suggested in the investigation of secondary causes of hypertension 
(158), this technique is weak in bilateral or segmental disease, and its use in the diagnostic 
algorithm of renovascular hypertension is not routinely advocated (159). The sensitivity and 
specificity of captopril renal scintigraphy for RVD are reported to be 59%–73% and 68%–
88% (160, 161). Although detection of segmental abnormalities is sometimes possible with 
this technique (162), the high prevalence of bilateral and/or branch artery RVD limit its utility 
in children. 
 
For the time being digital subtraction angiography (DSA) is the cardinal investigation in the 
assessment of paediatric RVD, due to its superior spatial resolution. In addition, DSA is the 
basis of endovascular intervention (163). Renal DMSA scanning has a role in monitoring the 
cortical function of a kidney supplied by a functionally significant artery stenosis before and 
after revascularization procedures such as angioplasty (158). A kidney supplied by a very 





Renal Vein Thrombosis 
In neonates, renal vein thrombosis (RVT) is usually related to venous stasis secondary to 
shock, septicaemia, or dehydration. The diagnosis may be suggested by the presence of 
oliguria, macroscopic haematuria, and proteinuria, with a clinically enlarged and hard kidney. 
RVT is also seen in infants of diabetic mothers and children with congenital heart disease. 
Nephrotic syndrome is a very frequent cause of large-vessel thrombosis because of urinary 
losses of antithrombin III, protein C, protein S, and other factors. The venous obstruction 
then leads to infarction and haemorrhage.   
 
Although RVT is associated with low mortality, the outcome of renal function is not always 
good, so these patients require close clinical follow up with serial sonography and a baseline 
DMSA scan at between six months and a year of age (164). In severe cases, there may be 
apparent function of the involved side. A follow up study may be useful to demonstrate the 
residual renal function after recovery. Radionuclide studies may reveal information of 
prognostic significance, with a normal study predicting a rapid and complete recovery. 




Renal infarction can occur in patients with cyanotic congenital heart disease, polycythaemia, 
atrial fibrillation, dehydration, or trauma. Aortic thrombosis and renal infarction are also well-
recognized complications of prolonged umbilical artery catheterization. Treatment with 
thrombolytic agents may allow resolution of the clot and recovery of renal function in some 
cases. DMSA scintigraphy demonstrates focal perfusion defect(s) in the affected kidney(s). 
	
	
UROLITHIASIS AND NEPHROCALCINOSIS 
Urolithiasis and nephrocalcinosis (NC) are two patterns of calcification associated with the 
urinary tract. Urolithiasis is macroscopic calcification in the urinary tract causing renal calculi. 
Urinary calculi are composed of crystal aggregates, sometimes mixed with proteins.  
Nephrocalcinosis represents increased calcium content in the kidney, in the form of 
microscopic calcification in the tubules, tubular epithelium, or interstitial tissue of the kidney. 
Nephrocalcinosis is not a uniform entity, but rather a complication of various renal disorders, 
metabolic disturbances or pharmacotherapy. Hypercalciuria appears to be the most common 
abnormality associated with NC (165). 
 
Urolithiasis in children is an increasingly common cause of morbidity and hospital 
admissions. Recent studies have shown that the incidence of urolithiasis in children has 
increased 6-10% annually during the past 25 years (166, 167). No one factor accounts for 
this dramatic increase; this is likely due to a combination of genetic predisposition, 
socioeconomic conditions and dietary intake.  Metabolic risk factors in paediatric urolithiasis 
can be identified in 75-84% of evaluated children (168, 169). 
 
Urolithiasis may be related to hypercalciuria, hyperoxaluria, hypocitraturia, cystinuria or 
hyperuricosuria. Additional risk factors for lithiasis include prematurity, urinary tract infection, 
urinary tract abnormalities, immobilization, chronic bowel disease and neurological 
disorders. Medications may be associated with an increased risk of nephrolithiasis, such as 
furosemide, vitamin D excess, vitamin C excess, topiramate and zonisamide.  
 
The most common symptoms of calculi are abdominal pain, sometimes clearly identifiable as 
colicky pain, vomiting, urinary tract infection, gross or microscopic non-glomerular 
haematuria and, more rarely, flank/loin tenderness or urinary retention. However, one in six 
children do not complain of any of these symptoms and their stones are detected 
unexpectedly on imaging (170). 
 
Renal calculi in children are treated by Extracorporal Shock Wave Lithotripsy (ESWL), Per-
Cutaneous Nephro-Lithotomy (PCNL), ureterorenoscopic retrograde intrarenal surgery and, 
less frequently, by open surgery or laparoscopy.  
 
With PCNL, stones are removed directly from the renal collecting system using keyhole 
access into the pelvi-calyceal system. PCNL is favoured in cases of renal stones of high 
density (Hounsfield Unit > 1000 on CT kidneys ureters bladder - KUB), stones situated in a 
dilated renal pelvis or a calyx from which fragments are unlikely to clear after ESWL, or 
when the calculus is stuck in a calyceal infundibulum causing obstruction to urinary outflow.  
 
ESWL is the preferred surgical technique in cases of less dense (Hounsfield Unit <500), 
renal stones up to 2cm in size, or in the presence of other comorbidities that preclude PCNL. 
This technique uses high energy sound waves to break a stone into small pieces that can 
more easily travel through the urinary tract and pass urethrally.    
 
Imaging 
Urinary tract calcification and stones are usually easily diagnosed by US, abdominal 
radiographs and low dose CT KUB, although small stones may not be detectable even when 
their presence is strongly suggested. Urolithiasis and NC can coexist in the same patient 
and NC may be permanent even after eliminating the cause.  
 
Most urinary tract calculi are visible on abdominal x-ray as a result of their calcium content, 
although fecal loading within the large bowel may obscure detail of the urinary tract and thus 
miss small calculi. A good quality ultrasound and an abdominal radiograph are therefore 
complementary techniques (171). CT is still commonly used to investigate suspected 
urolithiasis in children, as the majority of institutions involved in acute paediatric care are 
adult-centred and thus influenced by adult-centred practices (172). CT should be reserved 
for problem solving or treatment planning, as it is more accurate in determining stone size 
and it also helps with the identification of ureteric stones.  
 
Functional imaging plays a role in selected patients. DMSA scan or MAG3 renogram 
contribute little to the management of a patient with a sub-centimetre parenchymal renal 
stone, with normal surrounding parenchyma visible on ultrasound. However, a DMSA scan is 
important in a child with renal stones complicated by UTI, particularly if recurrent, as it will 
show possible renal scarring of the surrounding renal parenchyma. A MAG3 with diuretic will 
demonstrate function and drainage of a kidney with a stone obstructing the infundibulum of a 
calyx or partially obstructing the renal pelvis.  
 
A DMSA scan with planar and tomographic images, with SPECT images co-registered to a 
contemporaneous CT scan (acquired either on a SPECT CT scanner or on a standalone CT 
scanner, with the images subsequently co-registered to the SPECT images) can be a helpful 
imaging technique to define the anatomy, determine the number and density of the stone(s), 
precisely localize the calculus in the renal collecting system, and to provide information on 
the function of the renal parenchyma adjacent to the stone, thereby guiding surgical decision 
making (Fig.5a,b,c). It will also help differentiate NC from calculi and identify any possible 
ureteric stones with their associated risk of obstruction.  
 
The latest CT scanners with paediatric friendly protocols, minimise radiation levels to a 
fraction of that of a plain abdominal radiograph (0.056mSv versus 0.7mSv) as well as 
allowing a very short acquisition time (only approximately1.5 seconds), thereby avoiding the 




CONGENITAL RENAL ANOMALIES 
Duplex 
A duplex collecting system refers to a kidney with two pelvicalyceal systems, generally 
defined as the upper and lower moieties. If the kidney has two ureters that connect 
separately into the bladder (double ureters), it is considered a complete duplication. In 
contrast, in a partial or incomplete duplication (Y duplication), a common single ureter enters 
the bladder. A bifid system is a form of duplication with two pelvicalyceal systems joining 
before or at the PUJ (bifid pelvis) (173). The upper moiety ureter tends to insert more 
caudally and medially into the bladder than the normally inserting lower moiety ureter. The 
lower moiety ureter is often affected by VUR, whereas the upper moiety ureter is associated 
with a ureterocele and therefore may obstruct.  
 
Ureteroceles are cystic dilatations of the distal segment of the ureter. This obstruction may 
lead to partial or complete loss of function of the upper moiety. The upper moiety ureter may 
also insert ectopically, such as in the vagina in a girl or below the bladder neck. If it is 
obstructed and thus atrophic and almost invisible on ultrasound, a girl may present with 
constant wetting. A careful high quality ultrasound may find the cryptic upper moiety, or an 
MRI urogram may show the ureter and its ectopic insertion. 
 
Functional imaging is very important. A MAG3 renogram may confirm the diagnosis of a 
duplex kidney, clarifying the ultrasound findings. The diagnosis of a duplex on MAG3 may be 
suspected by differential tracer uptake in the upper and in the lower moiety; the tracer 
distribution in the collecting system during the drainage phase of the renogram can also 
suggest the presence of a duplex if tracer is seen in two complete separate collecting 
systems not merging into a common pelvis.  
If the upper moiety of a duplex is obstructed by a ureterocele, it may show very poor or no 
function on DMSA or MAG3. It may not be visible on functional imaging and therefore the 
ultrasound should be scrutinized for the presence of a duplex (Fig.6a,b). 
 
Vesico-ureteric reflux is the most common anomaly associated with renal duplex systems. 
VUR may occur in both moieties, but it is much more frequent into the lower moiety. The 
ureter draining the lower moiety of a duplex kidney opens more laterally in the bladder. This 
type of VUR may be associated with renal damage of the corresponding lower pole. A MAG3 
renogram with an indirect cystogram can provide accurate information on the cortical 
function of each moiety of the duplex kidney, as well as show the presence of VUR. Vesico-
ureteric reflux into a lower pole still has a potential of spontaneous resolution just as VUR 
into a single collecting system can spontaneously resolve (174-176). If the child is not toilet-
trained, reflux may be seen during the dynamic renography itself, if the child voids in the 
nappy (Fig.7). In this case, a catheter cystogram may be avoided. Reflux in an obstructed 
upper moiety, draining via a dilated and tortuous ureter due to the presence of a ureterocele 
is very uncommon; however, it is demonstrated in approximately 30% of duplex kidneys 
following puncture of the ureterocele.  
 
The treatment depends on the function of the affected moiety and the presence of 
symptoms, and it varies from conservative management with or without prophylactic 
antibiotics, to surgery. Management of a refluxing duplicated ureter depends on the function 
of the lower pole. Lower grades of reflux with good function may resolve spontaneously as 
the child grows. Higher grades of reflux may benefit from re-implantation of the ureter, if the 
refluxing lower moiety shows maintained parenchymal function, or lower pole 
heminephrectomy if the lower moiety functions poorly. A poorly functioning upper moiety of a 
duplex is usually treated with upper pole heminephrectomy. 
 
Ectopic Kidney 
Single renal ectopia refers to a kidney that remains in the ipsilateral retroperitoneal space, 
the most common position being the pelvis. Ultrasonography can make the diagnosis in the 
majority of cases. One or both kidneys may be ectopic in association with, or independent of, 
other renal malformations. Scintigraphy with DMSA is very useful to estimate the contribution 
of the ectopic kidney to total renal function: an anterior view is required in all cases, with the 
split renal function calculated using the geometric mean, in view of the asymmetric position 
compared to the contralateral kidney and the attenuation artefact from the renal pelvic bones 
in the posterior view. A MAG3 can be helpful to evaluate drainage, as this can be slow due 
to the possible high insertion of the ureter in the renal pelvis.  
 
 
Horseshoe Kidney and crossed renal ectopia 
Horseshoe kidneys are characterised by fusion of the lower poles across the midline by an 
isthmus lying anteriorly to the aorta and inferior vena cava. Radionuclide studies are useful 
to confirm the diagnosis (which may be unsuspected on ultrasound in view of the overlying 
bowel gas) and to look for possible functional abnormalities such as infection, hypertension, 
and haematuria. DMSA imaging (including anterior views or SPECT imaging) shows the 
function of the renal parenchyma and whether the kidneys are joined by functioning renal 
tissue or by a fibrous band.  
 
Pelvic-ureteric junction obstruction in one of the moieties of a horseshoe kidney is common, 
due to high insertion of the ureter or to an anomalous crossing renal vessel. A MAG3 
renogram will confirm the diagnosis and assess the drainage, confirming the level of 
possible urinary stasis. Renal calculi develop in 20% of patients with horseshoe kidneys 
(177).  
 
Crossed renal ectopia is the second most common fusion anomaly after the horseshoe 
kidney. Crossed renal ectopia with fusion is much more common than without fusion. There 
are many possible combinations of crossed renal ectopia. The crossed ectopic side lies on 
the opposite side to the ureteral insertion in the bladder. It may be difficult to differentiate a 
crossed fused kidney from a crossed kidney without fusion on ultrasound. A functional 
assessment with DMSA (better if supplemented with SPECT imaging) is often required to 
evaluate renal parenchymal integrity and confirm the diagnosis. If further anatomical details 
are required, especially with regard to vascular supply, ultrasound and MRI urography are 
the imaging methods of choice in children.   
 
Renal Hypoplasia 
This condition originates from disturbed differentiation of metanephrogenic tissue or 
problems with the induction of tissue differentiation. Histologically, it is defined by reduction 
in the number and/or size of nephrons, mostly in combination with dysplastic elements. 
Many children are otherwise healthy, and renal hypoplasia is detected by chance; others 
with more severe and bilateral disease may suffer from renal failure, urinary tract infection, 
and hypertension.  
 
Imaging usually starts with US. Volume calculations show a small kidney with otherwise 
often normal sonographic appearance. Additional work up is performed with MCUG to rule 
out VUR as a possible cause for a radiologically small kidney. A DMSA scan is very useful to 
confirm the diagnosis: this shows homogenously reduced tracer uptake, with no evidence of 
focal cortical defects.  
 
Multicystic Dysplastic Kidney  
Multicystic dysplasia of the kidney (MCDK) is the most common cystic disorder of infants 
and children with an incidence of about 1 in 4,000 births	and is more common in males 
(2.4:1). By definition, the affected kidney is non-functioning and is usually associated with an 
atretic ureter.	 
 
The aim of imaging in MCDK is to establish the diagnosis, confirm a normal contralateral 
renal unit, and to rule out associated anomalies. Imaging is initially performed with US (178). 
Associated urinary tract anomalies are present in one third of patients (PUJ urinary stasis in 
12%, VUR in 20%).Scintigraphy with DMSA shows no tracer uptake in the MCDK, 
confirming absence of cortical function, and dynamic renography will confirm normality of the 
contralateral kidney. MCDK may involve a portion of a duplex (usually the upper moiety) or 
of a horseshoe kidney. 
 
The majority of MCDKs involute during the first decade of life. Previously, MCDK was 
managed with nephrectomy to prevent potential development of proteinuria, hypertension, 
and degeneration into Wilms’ tumor. Several large studies have since shown these risks to 
be extremely low if present at all (179, 180). 
 
Conservative management with serial ultrasounds is now standard practice for MCDK (181). 
While exact imaging protocols vary, renal US is often performed every 3 to 6 months in the 
first 2 years and annually thereafter.	Cystograms are unnecessary in isolated MCDK with a 
normal contralateral kidney.  
 
Nephrectomy is only reserved for cases where the large size of the kidney is causing 
abdominal distension, discomfort, pain, difficult feeding or respiratory compromise in the first 
few months of life, where the cysts continue to increase in size and in case of hypertension. 
Failure to regress is considered by some as a relative indication for surgery. 
 
Cystic Renal Disease 
Cystic renal disease includes a variety of entities. Inherited diseases as well as a disturbed 
renal embryogenesis and renal development create a wide spectrum of manifestations that 
spans diffuse, severe, bilateral congenital disease to simple, single renal cysts occurring in 
the adult.  
 
Imaging in cystic kidneys always starts with ultrasound. Functional imaging is occasionally 
requested to evaluate the amount of cortical function present, especially if the condition is 
unilateral. Occasionally it may be difficult to distinguish a single cyst from a dilated calyx. A 
MAG3 renogram with delayed images can be helpful: a cyst will remain photopaenic on 




LOWER URINARY TRACT DYSFUNCTION (LUTD) 
 
Voiding Dysfunction 
Non-neurogenic bladder-sphincter dysfunction (“voiding dysfunction”) is a very common 
childhood disorder that all paediatric urologists, paediatricians and paediatric radiologists 
encounter in their daily practice. The most common clinical presentations are recurrent UTIs, 
VUR, and daytime and night-time urinary incontinence.  
 
Two main entities have been identified: overactive bladder (or unstable bladder, urge 
syndrome) and dysfunctional voiding. The common denominator of lower urinary tract 
dysfunction is bladder sphincter disco-ordination leading to chronic high intravesical 
pressure, with resulting negative consequences for the urinary tract. 
 
Nuclear Medicine may have a potential role in the screening for LUTD, through the use of 
the indirect cystogram supplemented by a non-invasive urodynamic bladder assessment 
with a flow meter. 
 
Overactive bladder (unstable bladder) 
The primary abnormality is the failure to suppress involuntary detrusor contractions due to 
the inability to exert complete voluntary control over the micturition reflex. The child, 
attempting to maintain continence during such contractions, must voluntarily and tightly 
constrict the external urethral sphincter to stay dry. This results in simultaneous and non-
physiological contraction of both the bladder and external urethral sphincter and leads to 
symptoms such as urgency, frequency and urge incontinence (overactive bladder syndrome) 
(182). The IRC study may show episodes of VUR with no micturition, in keeping with 
ineffective bladder contractions. 
 
Detrusor-sphincter dysfunction during micturition (dysfunctional voiding) 
The primary abnormality of this dysfunction is overactivity of the sphincter mechanism during 
voiding. 
 
Dysfunctional voiding can be subdivided into the following types: 
• Staccato voiding is caused by bursts of pelvic floor activity during micturition resulting 
in peaks in bladder pressure together with interruption in urinary flow; 
• Interrupted voiding is caused by hypoactivity of the detrusor muscle, with voiding 
consisting of several unsustained detrusor contractions each with its own flow. 
Voiding frequency tends to be low; bladder capacity is large; 
• Lazy bladder syndrome is the consequence of long-standing dysfunctional voiding. It 
results from detrusor decompensation. Abdominal pressure is mostly responsible for 
voiding. Large volumes of urine can be observed (183). 
 
High intravesical pressure is the main mediator that leads to morphologic changes of the 
urinary bladder in terms of trabeculation and formation of diverticula, and this may lead to 
VUR.  
 
There is a clear co-prevalence between LUTD and VUR. Lower urinary tract dysfunction 
refers to the presence of lower urinary tract symptoms, including urgency, urge-incontinence, 
weak stream, hesitancy, frequency and UTIs, which reflect the filling and/or emptying 
dysfunction. The development of VUR may be caused by the anatomical distortion of the 
vesico-ureteric junction as a consequence of chronic high pressure; high pressure itself does 
not cause VUR In cases of borderline competent ureteric orifices, chronic high pressure itself 
may directly induce and perpetuate VUR. 
 
A modified IRC with the addition of a flow meter may be a possible screening test for bladder 
function, while at the same time looking for VUR and assessing the function and drainage of 
the upper tracts (Fig.8a-e). The child sits on the commode and voids in a jug placed on the 
flow meter platform, with wireless connection to a computer. The platform is sensitive to the 
pressure of the jet of urine. This non-invasive urodynamic assessment informs on voiding 
time, time to maximum urine flow, maximum urine flow in ml/sec, and average flow. The 
shape of the bladder contraction curve gives some insight into bladder function. A normal 
bladder contraction curve typically has a bell shape, reflecting a harmonious synchronous 
and efficient contraction. Fractionated voiding is reflected by a bladder contraction curve with 
multiple spikes. Lazy bladder syndrome will show as incomplete bladder emptying over a 
prolonged period of time, with an elongated bladder contraction curve and multiple small 
spikes on the flow meter study. It is important to take note of the voided volume of urine: a 
large voided volume, in excess of that expected for a child of that particular age (see 
previous formula to calculate the expected voided volume for age), raises the possibility of a 
decompensated bladder. Conversely, if the child passes very little urine, this may mean that 
they were not well hydrated and therefore the IRC may be suboptimal.  
 
The IRC supplemented with a flow meter study may potentially be a screening tool for 
bladder dysfunction and direct patients to a comprehensive urodynamic bladder 
assessment. This approach needs proper evaluation. If VUR is detected, the initial goal of 




Children with neuropathic bladder-sphincter dysfunction may be unable to retain urine 
normally, to evacuate normally, or both. Most neurological conditions in children leading to a 
neuropathic bladder dysfunction include myelo-meningocele, lipomeningocele, sacral 
agenesis, and occult lesions such as congenital neurospinal dysraphisms (184). Children 
after sacrococcygeal teratoma resection may also develop a neuropathic bladder (185). The 
neuro-urological changes may arise from the tumor itself due to spinal compression and/or 
from the surgery. Therapeutic goals in children with neuropathic bladder are the preservation 
of renal function, avoidance of urinary tract infection, and achievement of appliance-free and 
social continence. 
 
Neuropathic bladder occurs also in 80%–90% of patients who suffer from myelodysplasia. 
Myelomeningocele is the most common defect. Neonatal assessment consists of an 
ultrasound of the bladder and kidneys and, in most centres, a MCUG as well. 
 
Although continence is readily appreciable by history, there is an insidious risk of renal 
damage. Therefore, regular assessment of the upper tracts with ultrasound is required to 
detect changes before irreversible damage has occurred. In these patients, renal 
scintigraphy with DMSA is used to monitor renal cortical function and to identify scars 




Radionuclide imaging is used infrequently in these patients. In the case of minor injuries, 
such as renal contusion, intra-renal and sub-renal haematoma, minor laceration without 
extension to the renal collecting system, or small subcortical infarcts, nuclear medicine 
investigations are usually not necessary, as management is conservative. CT is the imaging 
modality of choice in the initial trauma staging. 
 
In the case of major injuries, for example major renal laceration extending through the cortex 
to the medulla and collecting system, patient’s management can vary. If the patient is 
haemodynamically stable, management can still be conservative. If the patient is unstable, 
surgical exploration is required. In this case, DMSA scintigraphy (if feasible, in view of the 
patient’s clinical conditions) may be helpful prior to surgery to assess viability of renal 
parenchyma. Renal scintigraphy with DMSA can be also used to assess recovery or residual 
damage several months after trauma. Studies using Tc-99m-MAG3 or Tc-99m-DTPA can 
effectively detect urinary leaks following trauma. 
 
 
RECIPIENTS OF RENAL TRANSPLANTS 
It is possible to assess perfusion of the transplant with scintigraphic methods during the early 
and late post-operative periods, and assist in the differential diagnosis of diminished graft 
function, which includes rejection, obstruction, and urinary leak (187). In practice, Doppler 
ultrasound is commonly used to assess renal perfusion; the ultrasound examination can also 
raise the suspicion of obstruction to outflow by showing increasing renal pelvic or ureteric 
dilatation in comparison to the baseline ultrasound. When rejection is suspected, a renal 
biopsy is usually performed, making scintigraphy assessment almost always unnecessary.  
 
Renal transplant recipients have a high incidence of UTIs. A DMSA scan is useful to assess 
the degree of renal damage after a UTI. A DMSA in renal transplant recipients a few weeks 
after transplantation may be a helpful baseline, particularly in those young renal transplant 
recipients with a previously unused of “hostile” bladder (such as in posterior urethral valves 
or augmented bladders). The acquisition of six views (anterior, posterior, right and left 
posterior obliques, right and left anterior obliques) is highly recommended for better 
visualisation of the transplanted kidney. A SPECT dataset is helpful where the transplant 
may be unusually positioned. 
 
Obstruction 
Urinary obstruction is a possible complication following renal transplantation. Obstruction 
soon after surgery may be due to oedema and/or inflammation in the region of the vesico-
ureteric junction, which may be temporary. Later, obstruction may be due to external 
compression, which may be caused by a lymphocele or surgical scars or by stenosis at the 
ureteral anastomosis site. Because the transplant ureter obtains its blood supply only from 
the graft, the distal ureter may be poorly perfused, which may result in distal ureteral scarring 
and obstruction. Partial or even total obstruction of a transplant kidney may be relatively 
asymptomatic, as the graft is not innervated. Diagnosis of partial obstruction is sometimes 
difficult, and radionuclide dynamic renography with furosemide may be helpful.  
 
Urinary Leak 
Urinary leak usually occurs in the first few months following transplantation. It can occur at 
the site of anastomosis of the transplant ureter or through necrosis of the distal transplant 
ureter related to diminished perfusion. In cases of suspected urinary leak following 
transplantation, multiple serial images, usually as part of a MAG3 renogram, can effectively 
detect the presence of urinary leak and urinoma (188). Renal scintigraphy with Tc-99m-
MAG3 can also be used to differentiate urinoma from lymphocele or seroma. On the series 
of scintigrams, the leakage appears as a focal or diffuse area of increasing tracer 
accumulation outside the confines of the transplant, the ureter, or the bladder. Urinoma 
usually appears as a photo-deficient area on early images (5–10 min), due to the presence 
of non-radioactive urine, with subsequent accumulation of tracer on later images. If the 
initially photopenic area does not concentrate radiotracer on later images, this region may 
represent a haematoma or a lymphocele.  
 
 
NUCLEAR MEDICINE IN SOME PAEDIATRIC NEPHRO-UROLOGICAL TUMOURS 
 
Wilms’ Tumours 
Wilms’ tumour (WT) is the most common renal tumour in children. It accounts for 6% of all 
paediatric malignancies; the overall survival at 5 years exceeds 90% (189). Most WTs 
contain a mixture of blastemal, stromal, and epithelial cell components in varying 
proportions. Up to 10% will demonstrate anaplasia, which is associated with a poorer 
prognosis (190). Prognosis depends mostly on stage at diagnosis and histologic 
components of the lesion (intermediate versus anaplastic histology).  
 
Treatment of WT is based on histopathology and the stage of the disease. Staging is based 
on surgical and imaging findings. The primary goals of surgery are tumour resection, 
resection of involved lymph nodes, and avoidance of tumour spillage. Adjuvant 
chemotherapy and radiation therapy depend on the extent of the disease (191, 192).   
 
Local tumour staging requires information on tumour location, size, local extension, vascular 
compression or invasion, and local lymph node metastases. Initial staging requires 
ultrasound, CT, MRI. Bone scan is used if there is suspicion of skeletal metastases; 
however, skeletal metastases in WT are rare. The most common site for metastases is the 
lungs, which are typically evaluated with chest CT.  
 
The use of FDG PET CT in WTs has not been fully tested. The studies available are 
preliminary and include few patients. Possible applications for FDG PET CT in WTs are 
evaluation of response to neo-adjuvant chemotherapy and recurrent or metastatic disease.  
 
Wilms’ tumours show intense FDG uptake (193, 194), in particular anaplastic tumours. Misch 
D et al. (194) found PET advantageous in ruling out residual disease after completion of first-
line treatment and in pre-therapeutic staging of relapsed patients. There was also a good 
correlation of standardised uptake value (SUV) and histological differentiation. Begent (193) 
showed that PET/CT findings following initial chemotherapy correlated with histologically 
confirmed viable tumour, presence of lung metastases and areas of anaplasia. Another 
study showed no significant correlation between FDG uptake and histopathology (192). FDG 
PET CT may have the potential of predicting WT response to chemotherapy, with a 
significant correlation between pathologic response and reduction of SUV before and after 
induction chemotherapy (195); however, in view of conflicting reports, further evaluation is 
needed.  
 
No systematic studies exist on the use of FDG PET CT in nephroblastomatosis, clear cell 
sarcoma, genito-urinary rhabdoid tumour, and renal cell carcinoma. A study to compare FDG 
uptake in WT and nephroblastomatosis would be particularly useful. 
 
DMSA SPECT CT studies are becoming increasingly useful in specialised centres where 
stage V bilateral WTs are managed. The bilateral disease most often occurs in children with 
a genetic mutation leading to a WT1 gene alteration (for example in Denys Drash syndrome) 
or in other syndromes associated with the development of WT such as Beckwith-
Wiedemann syndrome. Nephron sparing surgery is being performed for bilateral disease in 
these high risk children, who may develop metachronous tumours. DMSA SPECT CT, with 
or without fusion of three dimensional contemporaneous MRI datasets, aids in attempting 
innovative preservation of renal tissue in those children who were previously rendered 




Most studies that evaluate FDG PET/CT in soft tissue sarcomas of childhood include small 
numbers and heterogeneous series of patients. Within this group of tumours, 
rhabdomyosarcomas of the genito-urinary tract constitute a small portion of paediatric 
rhabdomyosarcomas (10% in some series, Casey et al (196).  
 
For the majority of these tumours, MRI and/or CT are used to define the primary tumour, and 
CT of the lungs is used to exclude pulmonary metastases. Reports of using 18 F-FDG PET 
are becoming more common in staging, assessing response to treatment, and detecting 
residual, recurrent, or metastatic disease. Several studies on heterogeneous groups of 
patients with soft tissue sarcomas showed that the sensitivity and accuracy of FDG PET in 
the detection of bony lesions was higher than Tc-99m-methylene-diphosphonate bone scans 
(197, 198) and cross-sectional imaging with CT and MRI (199). 
 
The presence of regional lymph node metastases is a strong prognostic factor in 
rhabdomyosarcoma patients (200). FDG PET/CT has been shown to be more accurate than 
conventional imaging for detection of lymph node metastases (201, 202). FDG PET-CT can 
also predict survival in paediatric sarcoma patients based on the metabolic activity of the 





Much ground has been covered since the introduction of nuclear medicine examinations in 
paediatric nephro-urology; however, scintigraphy still has a significant role to play. High 
quality examinations that address a specific clinical question, complemented by a fully 
informative report that takes into account all the previous imaging and clinical details, are 
essential. Detailed guidelines on the acquisition and interpretation of the different 
radionuclide techniques have been published and are widely available on-line, leaving no 
room for unapproved and untested protocols.  
 
It is important to be aware of the already available applications of radionuclide imaging in 
congenital renal anomalies, renal calculi, and renovascular disorders with hypertension. The 
availability of SPECT supplemented by low dose child friendly CT acquisition parameters 
has significantly improved the diagnostic yield of DMSA scanning in urolithiasis. 
 
Research that can answer some important clinical questions is needed. Long-term 
appropriately powered cohort studies need to fully inform on the clinical significance of 
different degrees of renal scarring in children with UTIs and the associated risk of 
hypertension, chronic kidney disease and, in females, complications in pregnancy. In the 
context of an ante-natally diagnosed hydronephrosis, only a fraction of patients are at risk of 
losing renal function if left untreated; in the others the renal pelvic dilatation undergoes 
spontaneous resolution with time. Currently, we still struggle to reliably identify the 
hydronephrotic kidney at risk. It is essential to further evaluate in large paediatric studies 
promising parameters, such as the cortical tracer transit time, for the identification of the 
kidney at risk.   
 
. 
Finally, in recent years new promising possible applications of FDG PET CT in sarcomas of 
the genito-urinary tract have been proposed; these need proper testing. The advent of 
MR/PET imaging will likely benefit the management of paediatric patients with urogenital 
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